Ocugen Outlicenses Gene Therapy Candidate OCU400 to Celairis Therapeutics for Asia-Pacific Region
Ocugen (NASDAQ: OCGN) has entered into an agreement with Australian biopharmaceutical company Celairis Therapeutics to license the exclusive commercialization rights for its gene therapy candidate, OCU400. The licensing deal covers specific geographic territories, including Australia, New Zealand, and the ASEAN region. This strategic move allows Ocugen to expand the reach of its therapeutic pipeline into the Asia-Pacific market through a specialized regional partner. While the financial specifics were not detailed in the announcement, the partnership aims to leverage Celairis's local expertise to advance the commercial potential of OCU400.
Tickers: $OCGN
Topics: commercialization rights gene therapy licensing agreement
Read the full article at Seeking Alpha
Part of the story Ocugen, Inc. - 8-K Filing (2 articles)